RARE.US Ultragenyx

Healthcare Biotechnology USA Stocks
16.70 USD
Close of Nov 18, 2026
12.73 39.89
Market cap
USD 1.70B
P/E
-
P/B
19.68x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is RARE.US undervalued?

Graham number

The Graham number of Ultragenyx cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ultragenyx fundamental analysis

No fundamental analysis for Ultragenyx yet.

Ultragenyx stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ultragenyx

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced …

Full company profile